TOKYO (Reuters) - Fujitsu Ltd, Mizuho Financial Group Inc, and drugmaker PeptiDream Inc said on Thursday they are forming a joint venture to develop treatments for COVID-19.
The new company, to be called PeptiAID Inc, will research and develop peptide therapeutics for the current SARS-CoV-2 virus and potential future coronavirus outbreaks, the companies said in a release.
The joint venture also includes Takenaka Corp and Kishida Chemical Co.
Reporting by Rocky Swift; Editing by Kim Coghill
Our Standards: The Thomson Reuters Trust Principles.